Ash 2022 movers – Glycomimetics shakes off its sickle cell past
Meanwhile, there was bad blood between cell therapy players and their investors.
Ash 2022 – fast production fails to cure Car-T's problem
Novartis and Gracell’s two-day manufactured Cars do not solve cell therapy’s biggest bottleneck – yet.
Ash 2022 preview – a new multiple myeloma mechanism makes a splash
Talquetamab gets top billing in Ash’s press programme, but the data raise important issues about the role of targeting GPRC5D.
Asco 2022 movers – cell therapy wins, but it’s not the whole story
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
Asco 2022 – Carvykti casts a long shadow
Arcellx, Gracell and Oricell work hard to prove that there is still space for new Car-T therapies in multiple myeloma.
Asco 2022 – great expectations for Adicet, Arcellx and PMV
Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
EHA 2022 preview – some good news at last
Positive data result in positive share price movements – something of a novelty in the current market.
